We empower people with innovative treatment solutions

 

 

 

A commercial stage pharmaceutical company with three revenue generating pharmaceutical products

 

 

Development pipeline targeting large medical needs

 

 

AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products

Key News

NOVEMBER 28, 2023
FDA has accepted the New Drug Application filing for OX124

NOVEMBER 2, 2023
Orexo Q3 2023 Interim Report

OCTOBER 27, 2023
Orexo welcomes Robin Evers as new board member

To read all NEWS go to Media in the top menu 

Key financial figures

Group net revenue

629 MSEK
Last Twelve Months, Q422-Q323

Group EBITDA

-98 MSEK
Last Twelve Months, Q422-Q323

US Pharma segment EBIT

285 MSEK
Last Twelve Months, Q422-Q323

Cash position

184 MSEK
Q323

News Flow

Regulatory Press Releases

To read all NEWS go to Media in the top menu